Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.23 | 0.07 | 0.04 | -0.37 |
| FCF Yield | 4.95% | -26.24% | -8.23% | -9.50% |
| EV / EBITDA | 66.77 | -8.01 | -10.29 | -10.63 |
| Quality | ||||
| ROIC | 1.94% | -11.16% | -12.83% | -22.24% |
| Gross Margin | 99.28% | 97.62% | 98.69% | 95.94% |
| Cash Conversion Ratio | – | 5.23 | 1.73 | 0.64 |
| Growth | ||||
| Revenue 3-Year CAGR | 411.03% | 423.19% | 528.04% | 506.96% |
| Free Cash Flow Growth | 138.82% | -99.31% | 59.27% | -10.53% |
| Safety | ||||
| Net Debt / EBITDA | 6.98 | -1.51 | -1.32 | -1.19 |
| Interest Coverage | 1.61 | -13.99 | -8.49 | -13.96 |
| Efficiency | ||||
| Inventory Turnover | 1.24 | 0.15 | 1.51 | 0.11 |
| Cash Conversion Cycle | -2,461.09 | -28,080.30 | -3,756.33 | -17,046.18 |